Lessons learned and implications of early therapies for coronavirus disease in a territorial service centre in the Calabria region: a retrospective study.

Abstract

BACKGROUND:

Monoclonal antibodies (mAbs) and antivirals have been approved for early therapy of coronavirus disease (COVID-19), however, in the real-life setting, there are difficulties to prescribe these therapies within few days from symptom onset as recommended, and effectiveness of combined use of these drugs have been hypothesised in most-at-risk patients (such as those immunocompromised) but data supporting this strategy are limited.

METHODS:

We describe the real-life experience of SARS-CoV-2 antivirals and/or monoclonal antibodies (mAbs) and focus on the hospitalisation rate due to the progression of COVID-19. Clinical results obtained through our risk-stratification algorithm and benefits achieved through a strategic proximity territorial centre are provided. We also report a case series with an in-depth evaluation of SARS-CoV-2 genome in relationship with treatment strategy and clinical evolution of patients.

RESULTS:

Two hundred eighty-eight patients were analysed; 94/288 (32.6%) patients were treated with mAb monotherapy, 171/288 (59.4%) patients were treated with antivirals, and 23/288 (8%) patients received both mAbs and one antiviral drug. Haematological malignancies were more frequent in patients treated with combination therapy than in the other groups (p = 0.0003). There was a substantial increase in the number of treated patients since the opening of the centre dedicated to early therapies for COVID-19. The provided disease-management and treatment appeared to be effective since 98.6% patients recovered without hospital admission. Moreover, combination therapy with mAbs and antivirals seemed successful because all patients admitted to the hospital for COVID-19 did not receive such therapies, while none of the most-at-risk patients treated with combination therapy were hospitalized or reported adverse events.

CONCLUSIONS:

A low rate of COVID-19 progression requiring hospital admission was observed in patients included in this study. The dedicated COVID-19 proximity territorial service appeared to strengthen the regional sanitary system, avoiding the overwhelming of other services. Importantly, our results also support early combination therapy: it is possible that this strategy reduces the emergence of escape mutants of SARS-CoV-2, thereby increasing efficacy of early treatment, especially in immunocompromised individuals.

• Authors: Vincenzo Scaglione, Salvatore Rotundo, Nadia Marascio, Carmela De Marco, Rosaria Lionello, Claudia Veneziano, Lavinia Berardelli, Angela Quirino, Vincenzo Olivadese, Francesca Serapide, Bruno Tassone, Helen Linda Morrone, Chiara Davoli, Valentina La Gamba, Andrea Bruni, Bruno Mario Cesana, Giovanni Matera, Alessandro Russo, Francesco Saverio Costanzo, Giuseppe Viglietto, Enrico Maria Trecarichi, Carlo Torti, IDTM U. M. G. COVID-19 Group
• Journal: BMC infectious diseases (BMC Infect Dis) Vol. 22 Issue 1 Pg. 793 (Oct 20 2022) ISSN: 1471-2334 [Electronic] England
• PMID: 36266619 (Publication Type: Journal Article)
• Copyright: © 2022. The Author(s).

Chemical References

• Antiviral Agents
• Antibodies, Monoclonal

Topics

• Humans
• SARS-CoV-2
• Secondary Prevention
• Retrospective Studies
• Antiviral Agents (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• COVID-19 Drug Treatment